Highly active antiretroviral treatment is compromised by viral resistance mutations. Transmitted drug resistance (TDR) is therefore monitored closely, but follow-up studies of these patients are limited. Virus from 1405 individuals diagnosed with HIV-1 in Denmark between 2001 and 2009 was analyzed for TDR, and molecularepidemiological links and progression of the infection were described based on data from standardized questionnaires, the prospective Danish HIV Cohort Study, and by phylogenetic analysis. Eighty-five individuals were found to be infected with virus harboring mutations resulting in a prevalence of 6.1%, with no changes over time. The main resistance mutations were nucleoside reverse transcriptase inhibitor (NRTI) mutation 215 revertants, as well as nonnucleoside reverse transcriptase inhibitor (NNRTI) mutation 103N/S and protease inhibitor (PI) mutations 90M and 85V. Phylogenetic analysis confirmed 12 transmission chains involving 37 TDR individuals. Of these 21 were also documented epidemiologically. The virus included in the transmission chain carried similar resistance mutations to the TDR index case, whereas controls chains from index cases without TDR were generally without resistance mutations. We observed no difference in progression of the infection between individuals infected with TDR and individuals infected with wild-type HIV-1. The prevalence of TDR is low in Denmark and transmission of dual-drug-resistant HIV-1 is infrequent. The TDR isolates were shown to originate from local patients failing therapy.
Introduction

H
ighly active antiretroviral therapy (HAART) suppresses plasma HIV RNA viral load (VL) to undetectable levels and the treatment has markedly improved the prognosis for HIV-infected individuals. 1 The effectiveness of the therapy may be hampered by antiretroviral drug resistance leading to incomplete inhibition of viral replication and eventually an increase in plasma VL. 2 In case the patient transmits the virus the newly infected individual will often harbor a virus with transmitted drug resistance (TDR).
A decrease in the prevalence of potential transmitters of drug resistance in Denmark has been reported based on the history and prevalence of virological failure. 3 In addition, we have described a declining trend in the incidence of patients who develop resistant virus strains in Denmark from 1998 to 2005. 4 The purpose of the present study was to describe the trend, epidemiology, and spread of transmitted drug resistance among newly diagnosed treatment naive HIV-1 patients in Denmark from 2001 to 2009.
Materials and Methods
Data sources
Blood samples from newly diagnosed treatment-naive patients from all Danish HIV-treating centers were collected prospectively for the national surveillance of transmitted drug resistance project (SERO) since 2001. Related epidemiological data, the first measurement of VL and CD4 T cell counts, were collected using a standardized questionnaire. Seroconverters were identified as patients having a negative test performed within 6 months prior to a positive test. Only samples with corresponding questionnaires were analyzed. All patients included in the study were assigned a unique identification number, which was linked to the Danish personal identification number, enabling us to avoid multiple registrations of the same patient. The SERO project is unique in its design since all HIV-treating centers in Denmark recruit the newly diagnosed patients for this study. This means that a large majority of the HIV-positive patients in Denmark are tested for genotypic resistance upon diagnosis.
Sequences from the Danish HIV Sequence Database (DHSD), a nationwide, prospective, population database of all genotypic HIV-1 resistance tests performed in Denmark after December 31, 1999, 4 were used in phylogenetic analyses together with sequences from the SERO project. Sequences in this database originate from patients on treatment.
Data from the SERO project were coupled with data from the Danish HIV Cohort Study (DHCS), which prospectively registers all HIV-1-infected individuals treated in Danish HIV clinics since January 1, 1998. 5 This is a nationwide, population-based cohort study with continuous enrollment.
Sample processing, resistance analysis
The sequences containing the reverse transcriptase and the protease gene were obtained through population-based sequencing using ViroSeq HIV-1 genotyping System v. 2 (Abbott Diagnostics, Foster City, CA). Based on alignment against the HXB2 consensus sequence, all sequences were analyzed according to the list of recommended mutations for surveillance of transmitted drug resistance by Bennett et al. 6 The prevalence of transmitted resistance was estimated based on the number of newly diagnosed patients holding a genotypic resistance test with one or more protease inhibitor (PI) or reverse transcriptase (RT) mutations from the list of Bennett et al. 6 
Phylogenetic analysis
The aim of the phylogenetic analysis was to identify possible links between sequences from HIV-1 patients with treatment failure in Denmark and sequences from the newly HIV-1-diagnosed individuals with transmitted drug resistance. We aligned 3900 sequences; 2730 sequences from patients with treatment failure from DHSD that had been analyzed at the Virus BL-3 laboratory from year 2000 to 2009, 85 sequences from patients harboring TDR, and 85 matched control sequences not presenting TDR, both from newly diagnosed patients. The control sequences were matched to the TDR sequences based on gender, hospital, risk group, and sample date.
For each subtype, sequences were aligned by Clustal W and manually refined in BioEdit. 7 Distance-based phylogenetic trees were generated using the Jukes-Cantor distance model of evolution using the software Geneious (v.5.0.4). 8 Bootstrap values were calculated on 1000 replicates of the aligned data set to demonstrate the statistical support of the branches.
As criteria for phylogenetically documented transmitted drug resistance, we chose a bootstrap value greater than 90%, and intracluster average branch lengths had to be less than 0.03 nt substitutions per site. 9 We classified phylogenetically documented transmission in ''transmission clusters'' and ''transmission pairs.'' Transmission clusters had to be made up of more than two TDR sequences with the previous mentioned criteria, and transmission pairs were made up of one TDR sequence clustering close to a sequence from a patient on treatment or another TDR sequence. A refined tree was made based on the identified TDR clusters and pairs, including a group of sequences from patients failing therapy found to be most closely related to the TDR sequences in our database.
To omit the potential bias caused by the presence of drug resistance mutations, the phylogenetic analyses were repeated after deleting all resistance codons present in our TDR population from the preliminary alignment.
Statistics
The prevalence estimate was stratified according to calendar periods, and trends over calendar time were analyzed by the Cochran-Armitage trend test. 10, 11 To describe the prognosis of the patients infected with TDR HIV-1 we compared CD4 T cell count and VL in 12-week intervals and time to death and/or AIDS for the two patient groups as described previously. 12 
Results
Patient characteristics
A total of 1405 patients were included in the study. The patients' characteristics at the time of HIV diagnosis are summarized in Table 1 , and included 1089 (78%) men and 313 (22%) women; three patients had chosen to be anonymous. The mean log 10 VL was 4.6 copies/ml [standard deviation (SD) 0.87] and the median CD4 T cell count was 330 cells/ll [interquartile range (IQR) 155-530]. A total of 194 individuals had converted serologically within a maximum of 6 months prior to the genotypic resistance test. Of the patients 843 (60%) were born in Denmark, of whom 83% were infected with subtype B and 501 (59%) reported homosexual transmission as the route of infection.
Mutation prevalence
Of the 1405 newly diagnosed individuals, we found 85 infected with transmitted resistance mutations, yielding a prevalence of 6.1% [95% confidence interval (CI) 4.9-7.4]. The prevalence of TDR did not vary over calendar time (test for trend, p = 0.2). Resistance mutations to nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) were more prevalent [2.9% (95% CI, 2.0-3.8) and 2.6% (95% CI, 1.9-3.6). respectively] than resistance to nonnucleoside reverse transcriptase inhibitor (NNRTI) [1.3% (95% CI, 0.7-2.0)]. Resistance to two drug classes was found in 14.3% (95% CI, 7.6-23.6) of the TDR cases, but we did not observe any triple-class resistance. Test for trends regarding resistance to each of the three drug classes showed no significant trend over time ( p nrti = 0.9, p nnrti = 0.5, p pi = 0.1). Looking at individuals who were reported to convert serologically within 6 months prior to diagnosis, we found 13 individuals infected with TDR, corresponding to a prevalence of 6.7%.
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The most prevalent transmitted resistance mutation was codon 215 revertants (rev) mutations, which occurred in 31.8% (95% CI, 22.8-42.8) of the individuals with transmitted resistance. Of the individuals, 10.6% (95% CI, 4.1-19.2) carried a mutation against NNRTI at codon 103N/S, and 7.1% [95% CI, 2.6-14.7] carried mutation 188C/H/L. Mutation 90M was found in 10.6% (95% CI, 5.0-19.2) of the individuals with transmitted resistance. In addition, we saw a high prevalence of PI resistance mutation 85V [18.8% (95% CI, 11.2-8.8)]. To determine the prevalence using a treatment failure algorithm we recalculated the resistance profile according to the Stanford Genotypic Resistance Interpretation Database (HIVdb) v.6.0.7. 13 The overall prevalence was reduced to 5% (n = 69), but still with no significant trend over time (test for trend p = 0.8). Table 2 shows the different resistance profile of the TDR patients as well as the resistance level. Based on the resistance profile of HIVdb we found 16 (18.8%) of the 85 TDR patients were infected with a susceptible virus. Only 28 (32.9%) were found to be infected with a high-level resistant virus according to the HIVdb algorithm.
Prognosis of TDR
Patients were followed for up to 192 weeks (44 months) after the start of medication. We compared the group of newly diagnosed patients with TDR to the group of newly diagnosed patients without TDR.
Of the 85 patients diagnosed with TDR 60 started treatment during the follow-up period. We observed no difference in changes in VL and CD4 T cell count between the two patient groups (see Fig. 1 ). Risk of development of AIDS or death was equal in the two study populations [hazard ratio adjusted for gender, age, and CD4 T cell count was 0.59 (95% CI, 0.3-1.1)]. Twenty-one TDR patients initiated suboptimal treatment regimens carrying resistance mutations to at least one of the prescribed drugs (as results from genotypic resistance test were not always available prior to treatment initiation). However, regardless of the treatment regimen the TDR patients performed equally well as the patients diagnosed without TDR (data not shown). In addition, we saw no difference in the prognosis of patients diagnosed with TDR when the patients were categorized into subtype B vs. non-B (data not shown).
Phylogenetic patterns of TDR
To study the relation between sequences of patients with TDR and sequences of treatment-experienced patients failing therapy, we aligned 2900 sequences from DHSD: 2730 sequences from patients failing therapy, 85 sequences from TDR patients, and 85 control sequences from newly diagnosed drug-naive patients harboring wild-type fully susceptible virus. The control group was matched to the TDR sequences regarding sample date, hospital, gender, and risk group.
For each subtype we searched for transmission clusters and pairs and found these within subtype B, D, and G. Within subtype D and G we found only one transmission pair, respectively, linking one TDR sequence to one treatment failing sequence. Both reported heterosexual risk behavior and possible origin of infection from Denmark. Of the matched control sequences, subtype non-B, only one cluster was found within subtype D (data not shown).
Within subtype B we found eight TDR-related transmission clusters and four TDR-related transmission pairs involving 37 patients; the similar number for the controls was 26, in five clusters and four pairs. In TDR clusters where a sequence from a treatment-failing patient could be linked, the transmitted resistance mutations was present both in sequences from newly diagnosed patients and in sequences from patients failing treatment. The phylogenetic relations of subtype B are illustrated in Fig. 2 , which contains transmission clusters and pairs of TDR and control patients together with the most closely related sequences from patients failing therapy in DHSD.
Phylogenetically we could identify transmission of NRTI mutations 41L, 67N, 69D, 70R, codon 215 rev, 219QE; NNRTI mutations 103N and 188L; and PI mutations 82L and 90M. Based on the size of the transmission cluster (higher than three treatment-naive patients) we saw phylogenetic evidence for onward transmission of PI mutation 85V, PI mutation 90M, NNRTI mutation codon 215 rev, and NNRTI mutation 188L, with each mutation present in individual monophyletic clusters.
The NRTI resistance mutation 215rev was transmitted in two monophyletic clusters containing sequences from three treatment-naive patients each. One of these clusters could be linked to a sequence from a patient failing therapy (C_52), a sequence containing RT mutation 215rev only. The sample The largest transmission cluster presented a transmission of PI mutation 85V and included sequences from 14 TDR patients. The bootstrap support for this cluster was 100% and the internal branch lengths were short, indicating that these sequences were part of a local transmission cluster. The cluster consisted of sequences from the homosexual risk group, diagnosed between year 2005 and 2009. The only surveillance resistance mutation present in this cluster was PI mutation 85V. Two sequences from patients failing therapy were located in close relation to this cluster. One sequence presented PI mutations 85V only (patient C_23) and the other sequence presented NRTI mutation 184V only (patient C_9). The later sequence was not related according to our cluster criteria (bootstrap < 90%). Sequence C_23 originated from a patient not exposed to PI.
The sequences from the 85 control patients clustered in five major clusters and contained 26 (41%) of the 62 subtype B sequences. These clusters were characterized by longer branches than the TDR related clusters, and the majority of the related treatment failing sequences were fully susceptible to the full range of HAART. Sequences presenting resistance mutations (C_27, C_66, and C_14) were characterized by originating from a sample date later than the sample date of the sequences from treatment-naive patients.
Omission of identified transmitted resistance mutations gave identical results in a repeated phylogenetic analysis (data not shown).
Most of the patients with sequences within clusters reported primarily homosexual contacts as risk behaviors. Of the 62 TDR patients harboring subtype B, 32 (51%) patients reported Denmark as the country of infection, and 21 (65%) of these could phylogenetically be documented as possible Danish transmissions. 
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Discussion
In this population-based study, we found a low and stable prevalence of TDR among newly diagnosed HIV-1 individuals in Denmark from 2001 to 2009. Most prevalent was mutations conferring resistance to NRTI and PI. Of the 85 individuals infected with TDR we were able to phylogenetically document 37 of these as transmission with Danish origin occurring in eight transmission clusters. Twenty-one could further be confirmed as of Danish origin, based on questionnaires. The TDR patients responded equally well to HAART based on VL and CD4 T cell count.
This study is nationwide and we have included all newly diagnosed patients followed at the Danish HIV treating centers. It is to our knowledge the only nationwide study that has compared sequences of TDR with sequences of treatment-experienced patients in a search for the spread and origin of TDR.
It should be noted that the genotypic resistance test applied in this study is population-based sequencing, and only quasispecies that make up more than 20% of the total viral population are registered. A study by Johnson et al.
14 found by real-time polymerase chain reaction (PCR), a prevalence of TDR of 17% in treatment-naive patients who lacked evidence of drug resistance through conventional sequencing. Evidently, real-time PCR might identify TDR in patients that appear to be wild-type by population-based sequencing, but the method can identify only predefined mutations, which results in a bias in the selection of mutations studied.
Due to resistant virus strains that revert back to wild-type strains, it is likely that an estimate of transmitted drug resistance based on acute and recent infection will be higher than an estimate based on recent and chronic infections among the newly diagnosed. This setting was shown in a study from Canada, in which a significantly higher proportion of TDR among recent infections vs. established infections (12.2% vs. 6.1%, respectively, p = 0.005) was reported. 15 It is well known that newly infected HIV patients drive transmission of HIV to a certain extent. 16 In addition, clear networks of forward transmission of drug resistance have been described in a cohort of primary HIV-infected individuals. 17 However, we did not observe an increased prevalence of TDR in the seroconverter group compared to the newly diagnosed group with unknown time of infection. Our study population, however, included only a fairly low proportion (13%) of seroconverters.
Patients infected with TDR treated in Denmark responded well to HAART regarding the suppression of VL and increase in CD4 count or time to AIDS/death during a follow-up period of 44 months. Our results support the results presented by Jakobsen et al. 18 in which a group of patients infected with TDR, identified either with population-based sequencing or with HIV-SNaPshot, responded equally well to treatment in terms of time to viral suppression or CD4 T cell count increase. Analyzing the prognosis of TDR we are well aware that the results present a small, exclusive patient group that is monitored closely, which increases the likelihood of successful treatment, in spite of a TDR HIV infection.
A majority of the patients starting HAART received a regimen that corresponded very well with the observed resistance mutations. The 21 patients who received suboptimal treatment responded equally well at the end of the 44-month follow-up. It is likely that most of these patients have changed treatment during the follow-up period. The positive prognosis of the TDR patients might be affected by the fact that only a third of the patients were infected with resistance mutations conferring high-level drug resistance according to the Stanford resistance algorithm v. 6.0.8. The remaining patients were infected with resistance mutations causing intermediate-, low-level, and potential low-level resistance. In addition, most of the patients harbored virus resistant toward one drug class, few were resistant to two drug classes, and none conferred triple class resistance.
FIG. 1.
Changes in viral load (fraction with viral load < 500 copies/ml) and median CD4 T cell count after start of highly active antiretroviral therapy (HAART) for newly diagnosed patients with transmitted drug resistance (TDR) (full line n = 70) and newly diagnosed patients without TDR (dotted line n = 1197).
PHYLOGENETICS OF HIV-1 TRANSMITTED DRUG RESISTANCE
FIG. 2.
F84 neighbor-joining tree depicting the phylogenetic relationships between pol sequences of subtype B TDR patients. TDR patients labelled A_number, TDR controls labelled B_number, sequences from DHSD labelled C_number. TDR clusters and TDR pairs (dark gray), control clusters and control pairs (light gray). The 05_DF was used as outgroup. Bootstraps for marked clusters were all 100, except one, which is indicated. Transmitted drug resistance mutations are indicated on the involved clusters.
In this study we were able to relate the TDR sequences to sequences from patients treated in Denmark who have had resistance tests performed. This means that the TDR sequences have primarily been compared to sequences from patients failing therapy in Denmark after year 2000. We were able to phylogenetically link 39 (44%) out of 85 patients infected with TDR to another Danish-originating HIV sequence. The 37 subtype B sequences grouped in eight larger transmission clusters and four transmission pairs.
This level of documented transmission may indicate that multiple discrete transmission pathways contribute to the observed rate of transmission of drug resistance. In two clusters, with transmission of PI mutation 90M and NRTI mutation 215rev, it was not possible to link the TDR sequences to sequences from patients failing treatment. As sequences might diverge more over time it is possible that the documented transmission is underestimated due to the criteria of phylogenetically documented transmission, and late presenters might produce sequences that diverge more from the ancestral strain due to the high mutation rate of HIV. It is possible that the low level of linking between TDR sequences to known Danish sequences indicates that the donor does not exist in our database due to migration, death, or lack of diagnosed virological failure or that the country imports a certain level of TDR based on infection acquired abroad.
One important phylogenetic finding was a transmission cluster of 14 TDR patients who all carried a single PI resistance mutation 85V. The patients in this cluster were diagnosed in years 2005-2009 indicating a continued circulation of 85V among MSM in the Copenhagen area. Mutation 85V was the most prevalent PI-related TDR mutation in our study and was found in 19% of the TDR patients. 85V is a nonpolymorphic mutation related to PI exposure in the Stanford database. 19 A study by Vora et al. found this mutation to be related to a reduced virological response when found in combination with other PI associated mutations. 20 In the group of TDR patients with 85V we found no additional PI-related mutations. The Stanford database scores a sequence with 85V as fully susceptible to all drugs. From a clinical view this mutation, found as a singleton, does not call for any precautions when initiating treatment and its positions as a TDR marker could be questioned. In the present study no hint of PI exposure or other PI-associated mutations was observed in the large cluster harboring 85V; however, excluding the 85V-harboring patients did not change any of the conclusions of the study. These findings may influence future perspectives of drug resistance mutations for surveillance of transmitted drug resistance.
In two monophyletic clusters of three treatment-naive patients we saw transmission of NRTI 215rev. Furthermore, 215rev was also the most prevalent TDR mutation found. It is likely that the high level of 215 revertants we see in this study is a late effect of the pre-HAART era of ZDV treatment in Denmark. Zidovudine (ZDV) has been part of the Danish first line recommendations of HAART treatment, and has been widely implemented also in the pre-HAART era. 21 Patients treated with mono and dual treatment in the pre-HAART era failed the treatment more often due to resistance development caused by, for example, RT mutation 215Y/F. Revertants of 215 (D/C/E/ S/I/V) are mutations caused by a single base-pair change in the nucleotide sequence, which gives the virus strain a better replicative fitness compared to the resistant codon 215Y/F. 22 Revertants of 215 can revert back to the resistant codon 215Y/F rather efficiently, 23 and continuous surveillance of the transmission of this mutation is essential due to the incipient phylogenetic transmission we describe here.
Onward transmission of NNRTI mutation 188L was found in one TDR cluster of sequences from four treatment-naive patients. In the TDR population we found 7.1% of the individuals carrying 188C/H/L. The resistance mutation confers decreased susceptibility toward efavirenz (EFV) and nevirapine (NVP). Since 2001 EFV has been part of the recommended first-line HAART in Denmark. Approximately 75% of the Danish patients treated with HAART are treated with a combination including EFV.
In Denmark first-line therapy has since 1999 been an NRTI/ NNRTI regimen and compliance with the guidelines is high. 24 Furthermore, the frequency of viral failure among patients initiating HAART without prior antiretroviral treatment is quite low. 25 This study demonstrates that treatment-naive, newly diagnosed individuals present a source of onward transmission of viral strains carrying resistance mutation, a trend also described by others. [26] [27] [28] [29] [30] In the present study TDR transmission clusters contained mainly sequences from homosexual men. In Sweden, Lindströ m et al. report a large onward transmission of M41L among newly diagnosed homosexual men. M41L was found to be stable for several years after transmission, but did not confer phenotypic resistance levels. 26 In addition, Yerly et al. report transmission of multiresistant strains, also among homosexuals as well as intravenous drug users in Switzerland. 28 A previous study described how virologic failure among Danish HIV-1 patients is declining, 3 as well as the development of resistance among patients treated with HAART. 4 In spite of this, we observe a constant prevalence of TDR among newly diagnosed individuals. A large part of the transmissions can be identified as of Danish origin. Whether this is due to remnants of TDR from the pre-HAART era cannot be determined from our data, and further analyses are needed to describe the Danish epidemic in greater detail.
